1. Home
  2. CRDF vs PCLA Comparison

CRDF vs PCLA Comparison

Compare CRDF & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

SELL

Current Price

$0.87

Market Cap

67.1M

Sector

Health Care

ML Signal

SELL

Logo PicoCELA Inc. American Depositary Shares

PCLA

PicoCELA Inc. American Depositary Shares

HOLD

Current Price

$6.16

Market Cap

78.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDF
PCLA
Founded
1999
2008
Country
United States
Japan
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Building Products
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
78.7M
IPO Year
2012
2024

Fundamental Metrics

Financial Performance
Metric
CRDF
PCLA
Price
$0.87
$6.16
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $5.14
N/A
AVG Volume (30 Days)
1.0M
★ 1.0M
Earning Date
11-12-2026
02-12-2027
Dividend Yield
N/A
N/A
EPS Growth
★ 27.37
N/A
EPS
N/A
★ N/A
Revenue
★ $365,993.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 49.61
N/A
52 Week Low
$0.71
$0.12
52 Week High
$3.31
$19.61

Technical Indicators

Market Signals
Indicator
CRDF
PCLA
Relative Strength Index (RSI) N/A 45.79
Support Level N/A $5.97
Resistance Level N/A $6.95
Average True Range (ATR) 0.00 0.48
MACD 0.00 -0.06
Stochastic Oscillator 0.00 7.51

Price Performance

Historical Comparison
CRDF
PCLA

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: